Adherence to medication for attention deficit/hyperactivity disorder: Does time frame matter?

Journal of Pharmaceutical Health Services Research

Volumn 2, Issue 3, 2011, Pages 157-163

  Khoza, Star ^a   Oladapo, Abiola O ^a   Barner, Jamie C ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

ADHD; Medication adherence; Time frame

Indexed keywords

CENTRAL STIMULANT AGENT; LONG ACTING DRUG; PRODRUG; SHORT ACTING DRUG;

ADOLESCENT; ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL EVALUATION; COMORBIDITY; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRESCHOOL CHILD; PRESCRIPTION; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT DURATION; TREATMENT OUTCOME; UNITED STATES;

EID: 80051811086     PISSN: 17598885     EISSN: 17598893     Source Type: Journal    
DOI: 10.1111/j.1759-8893.2011.00054.x     Document Type: Article

References (27)

1. American Psychiatric Association, American Psychiatric Association, Task Force on DSM-IV. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR, 4th edn. Washington, DC: American Psychiatric Association, 2000.
2. Center for Disease Control and Prevention. Attention deficit/hyperactivity disorder (ADHD): Data & Statistics. 2006. (accessed 8 November 2010).
3. Matza L etal. A review of the economic burden of ADHD. Cost Effect Resour Allocat 2005; 3: 5.
4. Escobar R etal. Worse quality of life for children with newly diagnosed attention-deficit/hyperactivity disorder, compared with asthmatic and healthy children. Pediatrics 2005; 116: e364-e369.
5. Klassen AF etal. Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder. Pediatrics 2004; 114: e541-e547.
6. Matza L etal. The link between health-related quality of life and clinical symptoms among children with attention-deficit hyperactivity disorder. J Dev Behav Pediatr 2004; 25: 166-174.
7. Bernfort L etal. ADHD from a socio-economic perspective. Acta Paediatr 2008; 97: 239-245.
8. Harpin VA. The effect of ADHD on the life of an individual, their family, and community from preschool to adult life. Arch Dis Child 2005; 90: i2-i7.
9. Pliszka S. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007; 46: 894-921.
10. Subcommittee on Attention-Deficit/Hyperactivity Disorder, Committee on Quality Improvement. Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics 2001; 108: 1033-1044.
11. The MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry 1999; 56: 1073-1086.
12. The MTA Cooperative Group. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder. Pediatrics 2004; 113: 754-761.
13. Abikoff H etal. Social functioning in children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment. J Am Acad Child Adolesc Psychiatry 2004; 43: 820-829.
14. Scheffler RM etal. Positive association between attention-deficit/hyperactivity disorder medication use and academic achievement during elementary school. Pediatrics 2009; 123: 1273-1279.
15. Lopez F. ADHD: new pharmacological treatments on the horizon. J Dev Behav Pediatr 2006; 27: 410-416.
16. Szymanski ML, Zolotor A. Attention-deficit/hyperactivity disorder: management. Am Fam Physician 2001; 64: 1355-1362.
17. Hack S, Chow B. Pediatric psychotropic medication compliance: a literature review and research-based suggestions for improving treatment compliance. J Child Adolesc Psychopharmacol 2001; 11: 59-67.
18. Gau SSF etal. Determinants of adherence to methylphenidate and the impact of poor adherence on maternal and family measures. J Child Adolesc Psychopharmacol 2006; 16: 286-297.
19. Swanson J. Compliance with stimulants for attention-deficit/hyperactivity disorder: issues and approaches for improvement. CNS Drugs 2003; 17: 117-131.
20. Perwien A etal. Stimulant treatment patterns and compliance in children and adults with newly treated attention-deficit/hyperactivity disorder. J Manag Care Pharm 2004; 10: 122-129.
21. Sanchez RJ etal. Assessment of adherence measures with different stimulants among children and adolescents. Pharmacother 2005; 25: 909-917.
22. Marcus SC etal. Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 2005; 159: 572-578.
23. Cascade E etal. Seasonality and the changing adult/child prescription ratios in ADHD therapy. Psychiatry (Edgemont) 2008; 5: 23-25.
24. Christensen L etal. Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population. Curr Med Res Opin 2010; 26: 977-989.
25. Hazell PL etal. Management of children prescribed psychostimulant medication for attention deficit hyperactivity disorder in the Hunter region of NSW. Med J Aust 1996; 165: 477-480.
26. Schachar RJ etal. Behavioral, situational, and temporal effects of treatment of ADHD with methylphenidate. J Am Acad Child Adolesc Psychiatry 1997; 36: 754-763.
27. Hugtenburg JG etal. Methylphenidate: use in daily practice. Pharm World Sci 2005; 27: 197-201.